Related references
Note: Only part of the references are listed.Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Preetesh Jain et al.
CLINICAL CANCER RESEARCH (2017)
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
Heidi D. Finnes et al.
LEUKEMIA & LYMPHOMA (2017)
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)
Tait D. Shanafelt et al.
LEUKEMIA & LYMPHOMA (2017)
Ibrutinib for patients with rituximab-refractory Waldenstrm's macro globulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib
Preetesh Jain et al.
CANCER (2017)
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Paul M. Barr et al.
BLOOD (2017)
Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059
Harriet S. Walter et al.
BLOOD (2017)
Ventricular arrhythmias and sudden death in patients taking ibrutinib
Benjamin L. Lampson et al.
BLOOD (2017)
Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation
Daniela Poli et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Steven E. Coutre et al.
CLINICAL CANCER RESEARCH (2017)
Waldenstrom macroglobulinemia: 2017 update on diagnosis, risk stratification, and management
Morie A. Gertz
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL
Philip A. Thompson et al.
BLOOD (2016)
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Harriet S. Walter et al.
BLOOD (2016)
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Kirsten Fischer et al.
BLOOD (2016)
Causes of Death and Influencing Factors in Patients with Atrial Fibrillation
Laurent Fauchier et al.
AMERICAN JOURNAL OF MEDICINE (2016)
Deregulation of NF-κB, ie, a useful PMBL marker
Paul M. Barr
BLOOD (2016)
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
Darryl P. Leong et al.
BLOOD (2016)
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
Anthony R. Mato et al.
BLOOD (2016)
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Philip A. Thompson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores
G. Y. H. Lip et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien et al.
LANCET ONCOLOGY (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia
Kami Maddocks et al.
SEMINARS IN ONCOLOGY (2016)
The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia
Kruti Sheth Nair et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
Samantha M. Jaglowski et al.
BLOOD (2015)
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2015)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain et al.
BLOOD (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Andrew H. Lipsky et al.
HAEMATOLOGICA (2015)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Andrew H. Lipsky et al.
HAEMATOLOGICA (2015)
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
S. Kamel et al.
LEUKEMIA (2015)
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants
Jan de Jong et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men
Ellen Scheers et al.
DRUG METABOLISM AND DISPOSITION (2015)
The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis
Chatree Chai-Adisaksopha et al.
BLOOD (2014)
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade et al.
BLOOD (2014)
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
Sarah E. M. Herman et al.
BLOOD (2014)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
Craig T. January et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
Jan A. Burger et al.
LANCET ONCOLOGY (2014)
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
S. Cheng et al.
LEUKEMIA (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib, Obinutuzumab, Idelalisib, and Beyond: Review of Novel and Evolving Therapies for Chronic Lymphocytic Leukemia
Clement Chung et al.
PHARMACOTHERAPY (2014)
MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
Lian Xu et al.
BLOOD (2013)
Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop
Roger G. Owen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary
G. Y. H. Lip
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
B cell receptor signaling in chronic lymphocytic leukemia
Jan A. Burger et al.
TRENDS IN IMMUNOLOGY (2013)
Rate or Rhythm Control for Atrial Fibrillation: Update and Controversies
Jason S. Chinitz et al.
AMERICAN JOURNAL OF MEDICINE (2012)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
The B-cell receptor signaling pathway as a therapeutic target in CLL
Jennifer A. Woyach et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
Marcus Duehren-von Minden et al.
NATURE (2012)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Reduced Phosphoinositide 3-Kinase (p110α) Activation Increases the Susceptibility to Atrial Fibrillation
Lynette Pretorius et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
Abdalla J. Mohamed et al.
IMMUNOLOGICAL REVIEWS (2009)
Rhythm control versus rate control for atrial fibrillation and heart failure
Denis Roy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Tec regulates platelet activation by GPVI in the absence of Btk
BT Atkinson et al.
BLOOD (2003)
PI3K in lymphocyte development, differentiation and activation
K Okkenhaug et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Signaling network of the Btk family kinases
Y Qiu et al.
ONCOGENE (2000)
Share Paper
